M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.82 EUR 2.09% Market Closed
Market Cap: 108.6m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

P/E
Price to Earnings

-4.5
Current
-6.1
Median
22.7
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-4.5
=
Market Cap
108.8m EUR
/
Net Income
-24.1m EUR
All Countries
Close
Market Cap P/E
FR
Maat Pharma SA
PAR:MAAT
108.8m EUR -4.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -179 646.3
US
Abbvie Inc
NYSE:ABBV
320.1B USD 63
US
Amgen Inc
NASDAQ:AMGN
150.5B USD 35.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD -250.9
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 903.4
US
Epizyme Inc
F:EPE
94.1B EUR -475.6
AU
CSL Ltd
ASX:CSL
135.4B AUD 33.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD 17.8
US
Seagen Inc
F:SGT
39.3B EUR -55.1
NL
argenx SE
XBRU:ARGX
34.5B EUR -130.7
Earnings Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average P/E: 210.6
Negative Multiple: -4.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 646.3 N/A
US
Abbvie Inc
NYSE:ABBV
63
412%
US
Amgen Inc
NASDAQ:AMGN
35.6
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -250.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
903.4
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -475.6 N/A
AU
CSL Ltd
ASX:CSL
33.1
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.7 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-3.5
2-Years Forward
P/E
-4.2
3-Years Forward
P/E
-15.3

See Also

Discover More